Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
Submitted by
admin
on September 25, 2018 - 9:42am
Source:
CP Wire
News Tags:
Takeda
Alunbrig
non-small cell lung cancer
Headline:
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
snippet:
Alunbrig achieved a 51% increase in progression free survival compared to crizotinib
Alunbrig received Breakthrough Therapy Designation from the FDA for the treatment of patients with ALK+ NSCLC whose tumors are resistant to crizotinib
Alunbrig has Orphan Drug Designation by the FDA for the treatment of ALK+ NSCLC, ROS1+ and EGFR+ NSCLC.
Do Not Allow Advertisers to Use My Personal information
